Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure
NCT00196625Phase 2Completed
- Sponsor
- ANRS
- Start
- Nov 2000
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of amprenavir, lopinavir and ritonavir in human immunodeficiency virus infection (HIV) (4 arms), sponsored by ANRS. Primary endpoint: Mean change of HIV RNA at 26 weeks. Started Nov 2000; status: completed.
02
Drugs
amprenavirlopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00196625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00196625.